Medicare is a health insurance program that caters to aging persons at a fee. While the program provides a range of benefits and different types of coverage, it has its issues. To help with this, individuals should consider enrolling in a Medigap or Advantage plan.
What is Medicare Advantage?
Medicare Advantage, which is sometimes referred to as Part C, is offered by private insurers and is basically an individual’s primary insurance. It provides all benefits under Medicare as well as additional ones, including vision, dental, hearing and fitness coverage.
Individuals eligible for the Advantage plan include younger individuals with disabilities, those aged 65 years and older, and those with end-stage renal disease.
Most Advantage plans have a $0 premium, so individuals need to consider all their options. On average, an individual on Medicare has more than 30 Advantage plans to choose from.
What is Medigap?
On the other hand, Medigap, which is also referred to as Medicare Supplement plans, is offered by private insurance companies to supplement what original Medicare covers.
Medigap has 10 plans to pick from, with the plans offering standardized coverage and paying for different things, including coinsurance and deductibles. The estimated average premium charged per month ranges between $150 to $200.
People who are 65 years and older should consider enrolling in Medigap. It should be noted that federal regulations don’t mandate insurance companies sell policies under Medigap to individuals aged 65 and below.
So, what’s the difference between the Advantage and Medigap plans?
For starters, Medigap has global travel coverage while Advantage offers only one-stop-shop coverage. Advantage is also $0 deductible for most plans while Medigap has monthly payments that may at times be expensive.
Additionally, Medigap policies do not cover prescription medications while most policies under the Advantage plan cover prescription drugs.
Can someone switch between these plans?
Individuals who would like to switch from Medigap to an Advantage plan can do so during the open-enrollment period, which runs from Oct. 15–Dec. 7 every year.
It is important to note that those wishing to switch to Medigap from an Advantage plan will need to drop the latter and start by enrolling in original Medicare. Persons wishing to do so can drop the Advantage plan during the open-enrollment period, which runs from Jan. 1–March 31 annually.
To choose the best plan for you, individuals should consider various factors including budget, health history, medication needs and preferred benefits offered by the different providers such as Astiva Health before making a decision.
NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Approximately 20% of people in the U.S. live in a rural area, and they face…
On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant…
Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer.…
Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been…
Many existing cancer treatments, such as chemotherapy and radiation, don’t distinguish between cancer cells and…
A study whose findings were recently published has provided insights into the cost of treating…